Cas:42327-52-6 7-Methoxychroman-4-one manufacturer & supplier

Chemical Name:7-Methoxychroman-4-one

CAS.NO:42327-52-6

Synonyms:5948;4H-1-Benzopyran-4-one, 2,3-dihydro-7-methoxy-;7-methoxy-2H,3H,4H-chromen-4-one;7-Methoxy-4-chromanone;T66 BO EVT&J IO1;7-Methoxy-2,3-dihydro-4H-chromen-4-one;6-methoxy-1-tetralone;2,3-Dihydro-7-methoxy-4H-1-benzopyran-4-one;7-Methoxychroman-4-one;ghl.PD_Mitscher_leg0.304;7-methoxy-2H-1-benzopyran-4-one;2,3-dihydro-7-methoxychromen-4-one

Molecular Formula:C₁₀H₁₀O₃

Molecular Weight:178.185

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:331.0±41.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.547

PSA:35.53000

Exact Mass:178.062988

LogP:1.95

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5948 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,3-dihydro-7-methoxychromen-4-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,J IO1 Use and application,T66 BO EVT&amp technical grade,usp/ep/jp grade.

Related News: The upstream of pharmaceutical intermediates is the basic chemical raw material industry. Basic chemical raw materials are bulk commodities and prices fluctuate greatly, which directly affects the production costs of enterprises. 7-Methoxychroman-4-one manufacturer ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.�� 7-Methoxychroman-4-one supplier The upstream of pharmaceutical intermediates is the basic chemical raw material industry. Basic chemical raw materials are bulk commodities and prices fluctuate greatly, which directly affects the production costs of enterprises. 7-Methoxychroman-4-one vendor It is delivered to hospitals and pharmacies until it reaches the patient. 7-Methoxychroman-4-one factory Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue.